The Leukemia & Lymphoma Society and its partners developed the LLS COVID-19 Patient Financial Aid Program to provide $250 for eligible blood cancer patients struggling with the economic hardship because of COVID-19.
Amgen, Inc., Bristol Myers Squibb Foundation, Foundation Medicine, Inc., Genentech, a member of the Roche Group, Incyte, MorphoSys Foundation, Servier Pharmaceuticals, Subaru of America, Inc., and Takeda Oncology are contributing to the program.
“Along with our partners, we anticipated that blood cancer patients would need help with non-medical expenses such as food and other household needs, and housing and transportation,” Louis J. DeGennaro, LLS president and CEO, said in a statement. “And we aim to raise up to $10 million to help even more patients during this crisis.”
LLS is providing free educational resources and support to patients through a series of blogs, webinars and chats led by medical professionals.
LLS is soliciting donations for the program. All donations contribute to LLS’s mission to find cures for blood cancers and to ensure patient access to care.
